Luke Evnin Sells 24,962 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 24,962 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44. Following the completion of the transaction, the director owned 2,490,865 shares in the company, valued at approximately $1,544,336.30. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total value of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total value of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.

Werewolf Therapeutics Stock Up 1.8%

Shares of Werewolf Therapeutics stock opened at $0.64 on Friday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.56 and a 52-week high of $2.38. The company has a market capitalization of $31.30 million, a P/E ratio of -0.40 and a beta of 0.77. The company has a 50 day moving average of $0.98 and a 200 day moving average of $1.27.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on HOWL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup cut shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Citizens Jmp cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Finally, HC Wainwright dropped their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Large investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in Werewolf Therapeutics in the 2nd quarter valued at $409,000. Citadel Advisors LLC purchased a new stake in shares of Werewolf Therapeutics in the third quarter valued at about $304,000. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Werewolf Therapeutics during the second quarter worth about $113,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter worth about $92,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.